Medicine Industry's Gateway to NICE

Elinzanetant is in clinical development for the treatment of vasomotor symptoms (hot flashes) in women undergoing the menopause. The menopause occurs between 45 and 55 years of age and is caused by declining hormone levels. The declining hormone levels mean that neurons (nerve cells) in the hypothalamus (small part in the brain) become hyperactive and […]

Tezepelumab is in clinical development for the treatment of severe chronic rhinosinusitis with nasal polyps. Chronic rhinosinusitis is a condition in which the lining of the sinuses (air-filled spaces behind the nose, eyes, and cheeks) becomes inflamed for more than 12 weeks. People with the condition may have nasal polyps which are growths inside the […]

Mirvetuximab soravtansine is in clinical development for the treatment of adults with advanced, platinum-resistant, high-grade epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer with high folate receptor-alpha expression. Epithelial ovarian cancer means the cancer started in the surface layer covering the ovary. The main symptoms are frequent swollen or bloated tummy, pain or […]

Vanzacaftor/tezacaftor/deutivacaftor is in development for the treatment of cystic fibrosis in patients with at least one F508del mutation (faulty gene). Cystic fibrosis is a rare, chronic, and life-shortening genetic disease caused by a faulty gene that affects the movement of salt and water in and out of cells. It is a progressive, multi-system disease that […]

Evolocumab is currently in clinical development for the prevention of major cardiovascular events in adults without prior heart attack or stroke who are at high risk of a cardiovascular event. Cardiovascular disease (CVD) is an umbrella term for all diseases of the heart and circulation. It includes everything from conditions that are inherited or that […]

Apremilast is being investigated for the treatment of moderate to severe plaque psoriasis in children and adolescents (aged 6 to 17 years old). Psoriasis is a skin disease that causes a rash with itchy, scaly patches, most commonly on the knees, elbows, trunk, and scalp. Plaque psoriasis is the most common, and is characterised by […]

I-131-Apamistamab is in clinical development for the treatment of adult patients with relapsed, or refractory acute myeloid leukaemia (AML), prior to bone marrow transplant. AML is a type of blood cancer where excess immature white blood cells are made by the bone marrow, these immature cells do not function like healthy blood cells in fighting […]

Omaveloxolone is in development for the treatment of patients with Friedreich’s Ataxia (FA). FA is an inherited disease that causes a range of symptoms including difficulty walking, inability to coordinate movements, muscle weakness, speech problems, damage to the heart muscle and diabetes. Patients with FA do not have enough frataxin, a protein that regulates iron […]

Pylera in combination with omeprazole is currently in development for the treatment of adults who test positive for Helicobacter pylori (H. pylori) with upper gastrointestinal symptoms. H. pylori infection occurs when H. pylori bacteria infect the stomach, which typically happens during childhood. The bacteria are usually passed from person to person through direct contact with […]

Vepdegestrant is in development for the treatment of patients with oestrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer, who previously received endocrine-based treatment. A locally advanced breast cancer is a stage 3 breast cancer where the cancer has spread from the breast to lymph nodes close to the breast […]

Pembrolizumab-vibostolimab with etoposide and platinum chemotherapy is in clinical development for the first-line treatment of extensive stage small cell lung cancer (SCLC). Extensive stage SCLC is when cancer cells form in the tissues of the lung and spread beyond the lung to other places in the body. Symptoms include chest pain, a cough that does […]

Datopotamab deruxtecan is in clinical development for the treatment of inoperable or metastatic HR-positive HER2-negative breast cancer after one or two lines of systemic chemotherapy. Breast cancer is the growth of abnormal cells in the breast which divide uncontrollably to eventually form a tumour. Breast cancers can also be hormone receptor positive (HR+), meaning that […]

Trastuzumab deruxtecan is in clinical development for the neoadjuvant treatment of high-risk HER2-positive early-stage breast cancer. Breast cancer is when abnormal cells in the breast begin to grow and divide in an uncontrolled way and eventually form a growth (tumour). Breast cancer that has not spread beyond the breast or the axillary lymph nodes is […]

Obecabtagene autoleucel is an advanced therapy medicinal product (gene therapy product) known as ‘Chimeric Antigen Receptor’ (CAR) T cell therapy which is in clinical development for relapsed/refractory B-cell acute lymphoblastic leukaemia (B-ALL) in adults. B-ALL is an aggressive type of leukaemia (cancer of the blood and bone marrow), that can progress rapidly without treatment and […]

Serplulimab with chemotherapy is currently in clinical development as a first-line treatment for extensive-stage small-cell lung cancer (SCLC). SCLC is a very aggressive form of cancer that forms in the tissues of the lungs and often goes undiagnosed until it’s more advanced, so the survival rate tends to be low. Extensive stage SCLC (ES-SCLC) is […]

Niraparib with pembrolizumab is in clinical development for the maintenance therapy of patients with later stages of non-small cell lung cancer (NSCLC) after first-line platinum-based chemotherapy with pembrolizumab. Lung cancer is the third most common cancer in the UK and about 47,000 people are diagnosed with it each year. When cancer starts in the lungs, […]

Eplontersen is currently in development for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN). Hereditary transthyretin amyloidosis with polyneuropathy (formerly known as Familial Amyloid Polyneuropathy) is a rare disease caused by mutations in the gene that codes for transthyretin and is characterised by a multisystem extracellular deposition of amyloid (abnormal fibrous, extracellular, proteinaceous deposits found […]

Xeomin (Botulinum neurotoxin type A) is in clinical development for the treatment of adults with lower limb and/or upper limb spasticity. Spasticity is a long-term symptom described as a pathological increase in muscle tension (hypertonicity) resulting from damages to the brain, spinal cord, or motor nerves associated with conditions such as stroke, traumatic brain injury […]

Remibrutinib is currently in clinical development for the treatment of chronic spontaneous urticaria (CSU) in adult patients inadequately controlled by H1-antihistamines. CSU is a distressing skin condition that is characterised by itchy and sometimes painful raised rash or patches for at least six weeks with no known obvious trigger. It may also be accompanied by […]

Acoramidis is in clinical development for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). ATTR-CM is an underdiagnosed, progressively debilitating, rare disease associated with high mortality. ATTR-CM occurs when a protein called transthyretin (TTR) becomes unstable and aggregates, forming amyloids, and deposits primarily in the heart, as well as other organs, known as transthyretin amyloidosis. This […]

Zanubrutinib, combined with an already licensed medicine, obinutuzumab, is in clinical development for the treatment of patients with relapsed or refractory B-cell follicular lymphoma. Follicular lymphoma is a slow-growing blood cancer that affects white blood cells. In follicular lymphoma, the affected white blood cells multiply abnormally and aggregate in certain parts of the body, such […]

Resmetirom is currently in clinical development for the treatment of non-alcoholic steatohepatitis (NASH). NASH is caused by an accumulation of fat in the liver that results in inflammation and damage to the liver. It belongs to a class of diseases known as non-alcoholic fatty liver disease (NAFLD); it is an advanced form of the disease. […]

Tazemetostat is in clinical development for the treatment of adult patients with relapsed orrefractory follicular lymphoma who have received at least two prior treatments. Follicularlymphoma is a cancer of a type of white blood cell called B lymphocytes, or B cells. In follicularlymphoma, B cells multiply quickly and live for too long, so there are […]

Capivasertib with paclitaxel is currently in clinical development for previously untreated locallyadvanced (inoperable) or metastatic triple-negative breast cancer (TNBC). TNBC is a rare form ofbreast cancer where the tumour cells do not have receptors for oestrogen, progesterone, or thehuman epidermal growth factor receptor 2 (HER2) protein. Symptoms of TNBC include: a newlump or thickening in […]

Capivasertib with fulvestrant is in development for the treatment of patients with locally advanced (inoperable) or metastatic Hormone Receptor-Positive (HR+) and Human Epidermal growth factor Receptor 2-Negative (HER2-) breast cancer. A locally advanced breast cancer is stage 3, where cancer has spread from the breast to areas close to the breast or to the chest […]

Givinostat is in clinical development for Duchenne muscular dystrophy (DMD). DMD is a geneticdisease that gradually causes weakness and atrophy (wasting) of the muscles. It mainly affectsboys, and usually starts before the age of six years. Patients with DMD lack normal dystrophin, aprotein found in muscles. Because this protein helps to strengthen and protect muscles […]

Leriglitazone is currently being developed to treat male patients with X-linked adrenoleukodystrophy (X-ALD). Adrenoleukodystrophy (ALD) is a degenerative condition where there is a build-up of substances known as “very long chain fatty acids” in tissues around the body, particularly in the brain, spinal cord and adrenal glands. There are three types of ALD: a cerebral […]